Alternatives to CRISPR Therapeutics

Scalable, one-time curative in-vivo gene editing therapies.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Developing disease-responsive advanced therapies through programmable gene control technology.

Developing magnetic cell delivery platform for advanced therapies.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Gene therapy company developing transformative treatments for severe genetic diseases.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

VI Therapeutics is developing novel therapies for rare genetic diseases.

Developing gene editing therapies for rare genetic diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.